All articles by
BD Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore
First-Ever Program in the Country to Offer At-Home Self-Collection of Samples for HPV Testing
US FDA grants orphan drug status to Immune-Onc’s CMML therapy
A Phase 1 dosage expansion clinical trial combining IO-202 with azacitidine is presently enrolling newly diagnosed CMML patients who have not yet taken any hypomethylating medications
DarioHealth acquires Twill to create digital health platform for chronic conditions
The deal is expected to enable Dario to create a complete digital offering in the market for chronic conditions including mental well-being, emotional health, maternal health, and chronic conditions
Regeneron’s linvoseltamab gets FDA priority review in R/R multiple myeloma
The bispecific antibody is intended to connect B-cell maturation antigen on various myeloma cells with CD3-expressing T cells to help T-cell activation and kill cancer cells
GE Healthcare, Pointcore, OSF HealthCare partner to improve patient care
The partnership is intended to boost clinical and operational efficiencies, standardise care delivery models and enhance patient outcomes across OSF HealthCare
US FDA grants fast track status to Certa’s FT011 for systemic sclerosis treatment
The fast-track status was based on findings of the previously announced Phase 2 trial that showed a clinically meaningful improvement in 60% of patients treated with FT011 400mg
Harrow grants Canadian rights for five ophthalmic products to Apotex
Under the agreement, Apotex will seek market approval in Canada for VEVYE, IHEEZO, and ZERVIATE in Canada, and will distribute VERKAZIA and OTC Cationorm PLUS in the country
Iovance’s Amtagvi gets FDA accelerated approval for advanced melanoma
Amtagvi is a prescription-based tumour-derived autologous T cell immunotherapy and is said to be the first and the only one-time, individualised T cell therapy to get FDA nod for a solid tumour cancer
Health Canada Approves Remsima SC for the Treatment of Inflammatory Bowel Disease
Remsima SC, the first subcutaneous infliximab, now approved in Canada for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease
On-Device AI Healthcare Company Noul Becomes First Korean Diagnostic Company to Join Swiss Malaria Group
Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that its European subsidiary (noul GmbH) has become an official member of the Swiss Malaria Group, a Swiss public, private, academic & civil society leadership network for a malaria-free world.